Rebastinib
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.
Product Specifications
CAS Number
[1020172-07-9]
Product Name Alternative
DCC-2036
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Bcr-Abl; FLT3; Src
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/DCC-2036.html
Concentration
10mM
Purity
99.91
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
CC(C)(C)C1=NN(C(NC(NC2=C(F)C=C(OC3=CC(C(NC)=O)=NC=C3)C=C2)=O)=C1)C4=CC=C5C(C=CC=N5)=C4
Molecular Formula
C30H28FN7O3
Molecular Weight
553.59
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MiRNA Reverse transcription fluorescence quantitative detection kit (All In One)
